S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.79 (+1.42%)
AAPL   116.45 (+0.55%)
MSFT   212.34 (+0.96%)
FB   266.87 (+1.90%)
GOOGL   1,485.40 (+1.35%)
AMZN   3,219.89 (+2.26%)
TSLA   448.13 (+4.46%)
NVDA   542.34 (+0.21%)
BABA   288.85 (-1.75%)
CGC   14.14 (-1.26%)
MU   47.67 (+1.51%)
GE   6.21 (-0.32%)
AMD   84.73 (+3.34%)
T   28.43 (-0.28%)
F   6.73 (+1.05%)
ACB   4.67 (+0.43%)
GILD   63.07 (-0.19%)
NFLX   525.96 (+5.19%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   24.00 (-0.37%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.79 (+1.42%)
AAPL   116.45 (+0.55%)
MSFT   212.34 (+0.96%)
FB   266.87 (+1.90%)
GOOGL   1,485.40 (+1.35%)
AMZN   3,219.89 (+2.26%)
TSLA   448.13 (+4.46%)
NVDA   542.34 (+0.21%)
BABA   288.85 (-1.75%)
CGC   14.14 (-1.26%)
MU   47.67 (+1.51%)
GE   6.21 (-0.32%)
AMD   84.73 (+3.34%)
T   28.43 (-0.28%)
F   6.73 (+1.05%)
ACB   4.67 (+0.43%)
GILD   63.07 (-0.19%)
NFLX   525.96 (+5.19%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   24.00 (-0.37%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.79 (+1.42%)
AAPL   116.45 (+0.55%)
MSFT   212.34 (+0.96%)
FB   266.87 (+1.90%)
GOOGL   1,485.40 (+1.35%)
AMZN   3,219.89 (+2.26%)
TSLA   448.13 (+4.46%)
NVDA   542.34 (+0.21%)
BABA   288.85 (-1.75%)
CGC   14.14 (-1.26%)
MU   47.67 (+1.51%)
GE   6.21 (-0.32%)
AMD   84.73 (+3.34%)
T   28.43 (-0.28%)
F   6.73 (+1.05%)
ACB   4.67 (+0.43%)
GILD   63.07 (-0.19%)
NFLX   525.96 (+5.19%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   24.00 (-0.37%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.79 (+1.42%)
AAPL   116.45 (+0.55%)
MSFT   212.34 (+0.96%)
FB   266.87 (+1.90%)
GOOGL   1,485.40 (+1.35%)
AMZN   3,219.89 (+2.26%)
TSLA   448.13 (+4.46%)
NVDA   542.34 (+0.21%)
BABA   288.85 (-1.75%)
CGC   14.14 (-1.26%)
MU   47.67 (+1.51%)
GE   6.21 (-0.32%)
AMD   84.73 (+3.34%)
T   28.43 (-0.28%)
F   6.73 (+1.05%)
ACB   4.67 (+0.43%)
GILD   63.07 (-0.19%)
NFLX   525.96 (+5.19%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   24.00 (-0.37%)
Log in
NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$5.54
+0.27 (+5.12 %)
(As of 10/1/2020 03:45 PM ET)
Add
Compare
Today's Range
$5.24
Now: $5.54
$5.78
50-Day Range
$4.17
MA: $4.75
$5.73
52-Week Range
$3.01
Now: $5.54
$8.30
Volume13,674 shs
Average Volume119,617 shs
Market Capitalization$255.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Evelo Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share

Profitability

Net Income$-85,470,000.00

Miscellaneous

Employees75
Market Cap$255.60 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$5.54
+0.27 (+5.12 %)
(As of 10/1/2020 03:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

How has Evelo Biosciences' stock been impacted by COVID-19?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 25.6% and is now trading at $5.49.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Evelo Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Evelo Biosciences
.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences Inc (NASDAQ:EVLO) announced its earnings results on Thursday, July, 30th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.08.
View Evelo Biosciences' earnings history
.

What price target have analysts set for EVLO?

5 brokers have issued 1 year price targets for Evelo Biosciences' stock. Their forecasts range from $6.00 to $17.00. On average, they expect Evelo Biosciences' stock price to reach $10.33 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts' price targets for Evelo Biosciences
.

Are investors shorting Evelo Biosciences?

Evelo Biosciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,380,000 shares, an increase of 16.0% from the August 15th total of 1,190,000 shares. Based on an average daily volume of 167,900 shares, the short-interest ratio is currently 8.2 days. Approximately 9.3% of the company's shares are sold short.
View Evelo Biosciences' Short Interest
.

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
  • Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
  • Mr. Jonathan Poole, CFO & Treasurer (Age 44)

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $5.49.

How big of a company is Evelo Biosciences?

Evelo Biosciences has a market capitalization of $253.29 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.